FDA Proposes To Rely On Industry-Driven Consensus Quality Standards In New Drug Reviews
Executive Summary
FDA’s drug center has proposed a new program that would allow pharmaceutical manufacturers to attest that drug products submitted for review conform to certain consensus quality standards. The agency said that such a program would improve drug quality, encourage the development of emerging technology and ensure smoother drug reviews.